Key Points
- John Kleckner bought 2,468 shares of Enovis on Nov. 25 at $30.32 each (~$74,830), increasing his holding 25.10% to 12,302 shares valued at about $373,000.
- Enovis shares trade around $30.27 with a 12‑month range of $25.47–$49.75, a market cap of $1.73B and a negative P/E (-2.12); analysts have a consensus rating of “Moderate Buy” with a $51.17 target (six Buys, one Sell).
- Institutional ownership is very high at about 98.45%, led by Vanguard, T. Rowe Price and Dimensional, which have recently increased their stakes.
Enovis Corporation (NYSE:ENOV - Get Free Report) insider John Kleckner acquired 2,468 shares of the stock in a transaction dated Tuesday, November 25th. The stock was acquired at an average price of $30.32 per share, for a total transaction of $74,829.76. Following the purchase, the insider directly owned 12,302 shares in the company, valued at approximately $372,996.64. This trade represents a 25.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.
Enovis Stock Down 0.1%
Shares of ENOV stock opened at $30.27 on Friday. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53. Enovis Corporation has a 12 month low of $25.47 and a 12 month high of $49.75. The stock has a market cap of $1.73 billion, a P/E ratio of -2.12 and a beta of 1.67. The company has a 50 day simple moving average of $30.70 and a two-hundred day simple moving average of $30.98.
Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings results on Monday, January 8th. The company reported $0.59 earnings per share for the quarter. The business had revenue of $383.81 million for the quarter. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. On average, research analysts expect that Enovis Corporation will post 2.79 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of analysts have commented on ENOV shares. Needham & Company LLC reduced their price target on Enovis from $57.00 to $49.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. UBS Group reduced their target price on shares of Enovis from $65.00 to $57.00 and set a "buy" rating for the company in a report on Friday, August 8th. Wells Fargo & Company raised their target price on shares of Enovis from $41.00 to $42.00 and gave the stock an "overweight" rating in a research note on Friday, November 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enovis in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group reduced their price objective on shares of Enovis from $70.00 to $58.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $51.17.
View Our Latest Analysis on ENOV
Institutional Trading of Enovis
Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Enovis by 2.0% in the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company's stock valued at $197,945,000 after purchasing an additional 125,460 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Enovis by 0.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 6,207,768 shares of the company's stock valued at $237,199,000 after purchasing an additional 44,632 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Enovis by 1.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company's stock valued at $90,156,000 after purchasing an additional 51,201 shares during the last quarter. Rubric Capital Management LP purchased a new position in shares of Enovis in the 3rd quarter worth $83,435,000. Finally, Hood River Capital Management LLC increased its holdings in shares of Enovis by 20.3% in the 2nd quarter. Hood River Capital Management LLC now owns 1,735,533 shares of the company's stock worth $54,426,000 after buying an additional 292,950 shares during the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.
About Enovis
(
Get Free Report)
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
